Thoracic surgery continues to evolve rapidly in lung cancer care, with new advances reshaping how surgeons diagnose, treat, and manage patients across all stages of disease.
The STS Best of Lung Cancer Science is back for 2026, bringing you timely, high-value, and easy-to-consume education highlighting the latest breakthroughs and practice-changing data from four of the world’s leading scientific meetings:
- European Lung Cancer Congress (ELCC)
- American Society of Clinical Oncology (ASCO)
- World Conference on Lung Cancer (WCLC)
- European Society for Medical Oncology (ESMO)
Curated and interpreted by thoracic surgeons for thoracic surgeons, this STS resource delivers direct access to the most important developments in lung cancer science—helping you stay current on emerging evidence, evolving standards of care, and innovation impacting clinical practice.
Best of Lung Cancer Science - European Lung Cancer Congress (ELCC)
In this episode, host Erin Gillaspie, MD, speaks with Jonathan Spicer, MD, to discuss key takeaways from ELCC, including the shifting boundaries of resection, the expanding role of systemic therapy, and the growing influence of biology, AI, and real-world data on lung cancer care.
2025 Best of Lung Cancer Science Archive
Revisit expert analysis and executive summaries from last year’s leading lung cancer meetings.
In this episode, Dr. Erin Gillaspie sits down with Brendon Stiles, MD, to discuss insights from ASCO, including perioperative immunotherapy, CheckMate 816, and expanding surgical boundaries.
Leah Backhus, MD, joins Dr. Gillaspie to explore key takeaways from WCLC, including how precision data, surgical restraint, and breakthrough immunotherapy are transforming care.
In this episode, Dr. Gillaspie speaks with Paula Ugalde, MD, to examine findings from ELCC, including restaging in the neoadjuvant era, redefining resectability, AI in multidisciplinary precision, and the de-escalation debate.
Jessica Donington, MD, and Christine Bestvina, MD, join Dr. Gillaspie to unpack key lung cancer advances from ESMO, including adjuvant ALK inhibition (ALINA, ELEVATE), perioperative immunotherapy (KEYNOTE-671), and the expanding neoadjuvant space in borderline resectable disease.
This educational resource is sponsored by AstraZeneca, whose support helps shine a spotlight on the groundbreaking work of thoracic surgeons and researchers committed to improving patient outcomes.
